BRAF and thyroid gland papillary carcinoma: Although the BRAF V600E mutation in papillary thyroid cancer is generally associated with aggressive phenotypes [13], higher rates of disease recurrence [14] and shorter disease-free and overall survival [13], this mutation cannot be considered as an independent poor-outcome prognostic factor [15]; however, it should be evaluated in association with other prognostic factors [16].